The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Imatinib Drug-Global Market Insights and Sales Trends 2025
Synopsis
Imatinib is a chemotherapy drug that acts by reducing or preventing the progression of cancer cells. This drug is used for the treatment of certain cancers such as chronic myeloid leukemia, acute lymphoblastic leukemia, gastrointestinal tumors, certain skin tumors (dermatofibrosarcoma protuberans), and myelodysplastic/myeloproliferative diseases.
The global Imatinib Drug market size is expected to reach US$ 3621.8 million by 2029, growing at a CAGR of 3.8% from 2023 to 2029. The market is mainly driven by the significant applications of Imatinib Drug in various end use industries. The expanding demands from the Chronic Myelogenous Leukemia, Gastrointestinal Stromal Tumors and Others,, are propelling Imatinib Drug market. Tablets, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Capsules segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Imatinib Drug, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Imatinib Drug market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Imatinib Drug market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Imatinib Drug sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Imatinib Drug covered in this report include Novartis, Glenmark Pharmaceuticals Ltd., Sun Pharmaceuticals, Actavis Generics, Dr. Reddy's Laboratories, Teva Pharmaceutical Industries Ltd., Sanofi S.A., Cipla Inc. and Apotex Inc., etc.
The global Imatinib Drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Novartis
Glenmark Pharmaceuticals Ltd.
Sun Pharmaceuticals
Actavis Generics
Dr. Reddy's Laboratories
Teva Pharmaceutical Industries Ltd.
Sanofi S.A.
Cipla Inc.
Apotex Inc.
Mylan Pharms Inc.
Global Imatinib Drug market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Imatinib Drug market, Segment by Type:
Tablets
Capsules
Global Imatinib Drug market, by Application
Chronic Myelogenous Leukemia
Gastrointestinal Stromal Tumors
Others
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Imatinib Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Imatinib Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Imatinib is a chemotherapy drug that acts by reducing or preventing the progression of cancer cells. This drug is used for the treatment of certain cancers such as chronic myeloid leukemia, acute lymphoblastic leukemia, gastrointestinal tumors, certain skin tumors (dermatofibrosarcoma protuberans), and myelodysplastic/myeloproliferative diseases.
The global Imatinib Drug market size is expected to reach US$ 3621.8 million by 2029, growing at a CAGR of 3.8% from 2023 to 2029. The market is mainly driven by the significant applications of Imatinib Drug in various end use industries. The expanding demands from the Chronic Myelogenous Leukemia, Gastrointestinal Stromal Tumors and Others,, are propelling Imatinib Drug market. Tablets, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Capsules segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Imatinib Drug, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Imatinib Drug market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Imatinib Drug market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Imatinib Drug sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Imatinib Drug covered in this report include Novartis, Glenmark Pharmaceuticals Ltd., Sun Pharmaceuticals, Actavis Generics, Dr. Reddy's Laboratories, Teva Pharmaceutical Industries Ltd., Sanofi S.A., Cipla Inc. and Apotex Inc., etc.
The global Imatinib Drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Novartis
Glenmark Pharmaceuticals Ltd.
Sun Pharmaceuticals
Actavis Generics
Dr. Reddy's Laboratories
Teva Pharmaceutical Industries Ltd.
Sanofi S.A.
Cipla Inc.
Apotex Inc.
Mylan Pharms Inc.
Global Imatinib Drug market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Imatinib Drug market, Segment by Type:
Tablets
Capsules
Global Imatinib Drug market, by Application
Chronic Myelogenous Leukemia
Gastrointestinal Stromal Tumors
Others
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Imatinib Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Imatinib Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Imatinib Drug Market Overview
1.1 Imatinib Drug Product Overview
1.2 Imatinib Drug Market Segment by Type
1.2.1 Tablets
1.2.2 Capsules
1.3 Global Imatinib Drug Market Size by Type
1.3.1 Global Imatinib Drug Market Size Overview by Type (2018-2029)
1.3.2 Global Imatinib Drug Historic Market Size Review by Type (2018-2023)
1.3.3 Global Imatinib Drug Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Imatinib Drug Sales Breakdown by Type (2018-2023)
1.4.2 Europe Imatinib Drug Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Imatinib Drug Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Imatinib Drug Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Imatinib Drug Sales Breakdown by Type (2018-2023)
2 Global Imatinib Drug Market Competition by Company
2.1 Global Top Players by Imatinib Drug Sales (2018-2023)
2.2 Global Top Players by Imatinib Drug Revenue (2018-2023)
2.3 Global Top Players by Imatinib Drug Price (2018-2023)
2.4 Global Top Manufacturers Imatinib Drug Manufacturing Base Distribution, Sales Area, Product Type
2.5 Imatinib Drug Market Competitive Situation and Trends
2.5.1 Imatinib Drug Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Imatinib Drug Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Imatinib Drug as of 2022)
2.7 Date of Key Manufacturers Enter into Imatinib Drug Market
2.8 Key Manufacturers Imatinib Drug Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Imatinib Drug Status and Outlook by Region
3.1 Global Imatinib Drug Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Imatinib Drug Historic Market Size by Region
3.2.1 Global Imatinib Drug Sales in Volume by Region (2018-2023)
3.2.2 Global Imatinib Drug Sales in Value by Region (2018-2023)
3.2.3 Global Imatinib Drug Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Imatinib Drug Forecasted Market Size by Region
3.3.1 Global Imatinib Drug Sales in Volume by Region (2024-2029)
3.3.2 Global Imatinib Drug Sales in Value by Region (2024-2029)
3.3.3 Global Imatinib Drug Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Imatinib Drug by Application
4.1 Imatinib Drug Market Segment by Application
4.1.1 Chronic Myelogenous Leukemia
4.1.2 Gastrointestinal Stromal Tumors
4.1.3 Others
4.2 Global Imatinib Drug Market Size by Application
4.2.1 Global Imatinib Drug Market Size Overview by Application (2018-2029)
4.2.2 Global Imatinib Drug Historic Market Size Review by Application (2018-2023)
4.2.3 Global Imatinib Drug Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Imatinib Drug Sales Breakdown by Application (2018-2023)
4.3.2 Europe Imatinib Drug Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Imatinib Drug Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Imatinib Drug Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Imatinib Drug Sales Breakdown by Application (2018-2023)
5 North America Imatinib Drug by Country
5.1 North America Imatinib Drug Historic Market Size by Country
5.1.1 North America Imatinib Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Imatinib Drug Sales in Volume by Country (2018-2023)
5.1.3 North America Imatinib Drug Sales in Value by Country (2018-2023)
5.2 North America Imatinib Drug Forecasted Market Size by Country
5.2.1 North America Imatinib Drug Sales in Volume by Country (2024-2029)
5.2.2 North America Imatinib Drug Sales in Value by Country (2024-2029)
6 Europe Imatinib Drug by Country
6.1 Europe Imatinib Drug Historic Market Size by Country
6.1.1 Europe Imatinib Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Imatinib Drug Sales in Volume by Country (2018-2023)
6.1.3 Europe Imatinib Drug Sales in Value by Country (2018-2023)
6.2 Europe Imatinib Drug Forecasted Market Size by Country
6.2.1 Europe Imatinib Drug Sales in Volume by Country (2024-2029)
6.2.2 Europe Imatinib Drug Sales in Value by Country (2024-2029)
7 Asia-Pacific Imatinib Drug by Region
7.1 Asia-Pacific Imatinib Drug Historic Market Size by Region
7.1.1 Asia-Pacific Imatinib Drug Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Imatinib Drug Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Imatinib Drug Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Imatinib Drug Forecasted Market Size by Region
7.2.1 Asia-Pacific Imatinib Drug Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Imatinib Drug Sales in Value by Region (2024-2029)
8 Latin America Imatinib Drug by Country
8.1 Latin America Imatinib Drug Historic Market Size by Country
8.1.1 Latin America Imatinib Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Imatinib Drug Sales in Volume by Country (2018-2023)
8.1.3 Latin America Imatinib Drug Sales in Value by Country (2018-2023)
8.2 Latin America Imatinib Drug Forecasted Market Size by Country
8.2.1 Latin America Imatinib Drug Sales in Volume by Country (2024-2029)
8.2.2 Latin America Imatinib Drug Sales in Value by Country (2024-2029)
9 Middle East and Africa Imatinib Drug by Country
9.1 Middle East and Africa Imatinib Drug Historic Market Size by Country
9.1.1 Middle East and Africa Imatinib Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Imatinib Drug Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Imatinib Drug Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Imatinib Drug Forecasted Market Size by Country
9.2.1 Middle East and Africa Imatinib Drug Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Imatinib Drug Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Novartis
10.1.1 Novartis Company Information
10.1.2 Novartis Introduction and Business Overview
10.1.3 Novartis Imatinib Drug Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Novartis Imatinib Drug Products Offered
10.1.5 Novartis Recent Development
10.2 Glenmark Pharmaceuticals Ltd.
10.2.1 Glenmark Pharmaceuticals Ltd. Company Information
10.2.2 Glenmark Pharmaceuticals Ltd. Introduction and Business Overview
10.2.3 Glenmark Pharmaceuticals Ltd. Imatinib Drug Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Glenmark Pharmaceuticals Ltd. Imatinib Drug Products Offered
10.2.5 Glenmark Pharmaceuticals Ltd. Recent Development
10.3 Sun Pharmaceuticals
10.3.1 Sun Pharmaceuticals Company Information
10.3.2 Sun Pharmaceuticals Introduction and Business Overview
10.3.3 Sun Pharmaceuticals Imatinib Drug Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Sun Pharmaceuticals Imatinib Drug Products Offered
10.3.5 Sun Pharmaceuticals Recent Development
10.4 Actavis Generics
10.4.1 Actavis Generics Company Information
10.4.2 Actavis Generics Introduction and Business Overview
10.4.3 Actavis Generics Imatinib Drug Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Actavis Generics Imatinib Drug Products Offered
10.4.5 Actavis Generics Recent Development
10.5 Dr. Reddy's Laboratories
10.5.1 Dr. Reddy's Laboratories Company Information
10.5.2 Dr. Reddy's Laboratories Introduction and Business Overview
10.5.3 Dr. Reddy's Laboratories Imatinib Drug Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Dr. Reddy's Laboratories Imatinib Drug Products Offered
10.5.5 Dr. Reddy's Laboratories Recent Development
10.6 Teva Pharmaceutical Industries Ltd.
10.6.1 Teva Pharmaceutical Industries Ltd. Company Information
10.6.2 Teva Pharmaceutical Industries Ltd. Introduction and Business Overview
10.6.3 Teva Pharmaceutical Industries Ltd. Imatinib Drug Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Teva Pharmaceutical Industries Ltd. Imatinib Drug Products Offered
10.6.5 Teva Pharmaceutical Industries Ltd. Recent Development
10.7 Sanofi S.A.
10.7.1 Sanofi S.A. Company Information
10.7.2 Sanofi S.A. Introduction and Business Overview
10.7.3 Sanofi S.A. Imatinib Drug Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Sanofi S.A. Imatinib Drug Products Offered
10.7.5 Sanofi S.A. Recent Development
10.8 Cipla Inc.
10.8.1 Cipla Inc. Company Information
10.8.2 Cipla Inc. Introduction and Business Overview
10.8.3 Cipla Inc. Imatinib Drug Sales, Revenue and Gross Margin (2018-2023)
10.8.4 Cipla Inc. Imatinib Drug Products Offered
10.8.5 Cipla Inc. Recent Development
10.9 Apotex Inc.
10.9.1 Apotex Inc. Company Information
10.9.2 Apotex Inc. Introduction and Business Overview
10.9.3 Apotex Inc. Imatinib Drug Sales, Revenue and Gross Margin (2018-2023)
10.9.4 Apotex Inc. Imatinib Drug Products Offered
10.9.5 Apotex Inc. Recent Development
10.10 Mylan Pharms Inc.
10.10.1 Mylan Pharms Inc. Company Information
10.10.2 Mylan Pharms Inc. Introduction and Business Overview
10.10.3 Mylan Pharms Inc. Imatinib Drug Sales, Revenue and Gross Margin (2018-2023)
10.10.4 Mylan Pharms Inc. Imatinib Drug Products Offered
10.10.5 Mylan Pharms Inc. Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Imatinib Drug Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Imatinib Drug Industrial Chain Analysis
11.4 Imatinib Drug Market Dynamics
11.4.1 Imatinib Drug Industry Trends
11.4.2 Imatinib Drug Market Drivers
11.4.3 Imatinib Drug Market Challenges
11.4.4 Imatinib Drug Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Imatinib Drug Distributors
12.3 Imatinib Drug Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
